MEK inhibitors in non-V600 BRAF mutations and fusions

Abstract

Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.

Keywords: BRAF; MEK; atypical; fusion; trametinib.